Mounjaro for Weight Loss: Off-Label Use, Risks, and Clinical Evidence

What Mounjaro Is and Why It Gets Prescribed Off-Label

Mounjaro (tirzepatide) is a once-weekly injectable peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The FDA approved it in May 2022 specifically as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [1]. It was not approved for weight loss under the Mounjaro brand.

The off-label pattern emerged quickly. Clinicians observed that tirzepatide produced substantial weight reduction in the diabetes trials (SURPASS program), and by mid-2022, prescriptions written for weight management began rising sharply. A GoodRx analysis reported that off-label weight-loss prescriptions for Mounjaro accounted for a significant share of total scripts within its first year on the market.

The distinction matters. In November 2023, the FDA approved the same molecule (tirzepatide) under a separate brand name, Zepbound [2], for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity. When a physician writes a prescription for "Mounjaro" rather than "Zepbound" to treat obesity, that prescription remains off-label regardless of Zepbound's approval. This affects insurance coverage, liability, and the informed consent conversation.

The Clinical Evidence: SURMOUNT Trial Program

The strongest evidence for tirzepatide in weight loss comes from the SURMOUNT program, a series of phase 3 randomized controlled trials enrolling adults with obesity or overweight but without type 2 diabetes.

SURMOUNT-1 (N=2,539) randomized participants to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo for 72 weeks [3]. Mean percent body weight reduction was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) compared with 3.1% for placebo. Among participants receiving the 15 mg dose, 36.2% lost 25% or more of their body weight. These results exceed anything previously reported in a pharmaceutical obesity trial.

SURMOUNT-2 (N=938) tested tirzepatide in adults who had both obesity and type 2 diabetes. At 72 weeks, the 15 mg group achieved 14.7% mean weight loss [4] versus 3.2% for placebo, with concurrent HbA1c reductions of 2.1 percentage points.

SURMOUNT-3 examined a sequential approach: 12 weeks of intensive lifestyle intervention followed by 72 weeks of tirzepatide or placebo. The tirzepatide group lost an additional 18.4% body weight beyond what the lifestyle phase had already achieved.

SURMOUNT-4 addressed the durability question. After 36 weeks of open-label tirzepatide (mean loss: 20.9%), participants were re-randomized to continue tirzepatide or switch to placebo for another 52 weeks. Those who continued lost an additional 5.5%. Those switched to placebo regained 14.0% [5]. This trial made one thing clear: stopping tirzepatide leads to substantial weight regain.

How Tirzepatide Compares to Semaglutide

No head-to-head trial between tirzepatide and semaglutide 2.4 mg (Wegovy) for weight loss has been published as of mid-2026. Cross-trial comparisons are imperfect but informative.

In STEP 1 [6] (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo. The highest tirzepatide dose in SURMOUNT-1 produced 20.9% at 72 weeks. The approximately 6 percentage point gap is consistent across multiple indirect comparisons, though differences in trial populations, baseline BMI, and lifestyle intervention intensity limit direct conclusions.

Dr. Ania Jastreboff, lead investigator of SURMOUNT-1 and associate professor of medicine at Yale School of Medicine, stated: "The dual agonism of GIP and GLP-1 receptors appears to provide additive or synergistic effects on body weight that go beyond single-incretin approaches."

A network meta-analysis published in JAMA found that tirzepatide 15 mg ranked highest among approved anti-obesity medications for percentage body weight reduction, with a mean difference of approximately 6 to 8 percentage points over semaglutide 2.4 mg [7]. The confidence intervals were wide but consistently favored tirzepatide at the highest dose.

One practical difference: tirzepatide's GIP receptor activity may contribute to fewer gastrointestinal side effects at equivalent weight-loss efficacy, though this has not been confirmed in a direct comparison trial.

Gastrointestinal and Other Common Side Effects

GI symptoms dominate the adverse event profile. In SURMOUNT-1, nausea occurred in 24.6% (5 mg), 33.3% (10 mg), and 31.0% (15 mg) of tirzepatide-treated participants versus 9.5% for placebo [3]. Diarrhea rates ranged from 18.7% to 23.0%. Vomiting affected 5.8% to 12.2%.

Most GI events were mild to moderate and concentrated during the dose-escalation phase (weeks 1 through 20). The protocol escalates from 2.5 mg every four weeks, reaching 15 mg by week 20 at the fastest schedule. Slowing the titration reduces symptom burden but delays peak efficacy.

Beyond the GI tract, clinically relevant adverse events include:

Gallbladder events. Cholelithiasis occurred in 0.6% to 1.7% of tirzepatide-treated patients versus 0.2% for placebo across the SURMOUNT program. Rapid weight loss itself is a known risk factor for gallstone formation, and this signal is consistent with the GLP-1 receptor agonist class [8].

Injection site reactions. Reported in 2% to 7% of participants. Typically mild erythema or pruritus.

Hypoglycemia. Rare in non-diabetic patients (<1%), but a real risk if combined with insulin or sulfonylureas in patients with diabetes.

Pancreatitis. Acute pancreatitis events were uncommon (<0.2%) in SURMOUNT trials, but the GLP-1 agonist class carries a labeled warning. Any patient with a history of pancreatitis should discuss this risk explicitly with their prescriber.

Discontinuation due to adverse events ranged from 4.3% (5 mg) to 7.1% (15 mg) in SURMOUNT-1. For context, the placebo group had a 2.6% discontinuation rate [3].

Lean Mass Loss and Body Composition Concerns

Weight loss from any intervention includes both fat mass and lean mass. The ratio matters.

In SURMOUNT-1, a DEXA substudy found that approximately 33% of total weight lost with tirzepatide 15 mg was lean mass [9]. This proportion is comparable to what is observed with caloric restriction alone and slightly better than the 35% to 40% lean mass loss reported in some bariatric surgery cohorts [9].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, noted: "Any time a patient loses 15% or more of body weight, we need to actively address lean mass preservation through resistance exercise and adequate protein intake, regardless of the mechanism of weight loss."

Practical recommendations based on current evidence: protein intake of 1.2 to 1.6 g per kilogram of ideal body weight daily, resistance training at least two to three sessions per week, and periodic body composition assessment (DEXA or bioimpedance) for patients losing more than 10% body weight.

The long-term musculoskeletal consequences of tirzepatide-induced weight loss in older adults (over 65) remain unstudied. This is a gap the field has not yet filled.

Insurance, Cost, and Access Barriers

Off-label Mounjaro prescriptions face significant insurance barriers. Most commercial payers and Medicare Part D plans require either a type 2 diabetes diagnosis for Mounjaro or a qualifying obesity diagnosis for Zepbound [2]. Prior authorization is nearly universal for both.

Cash prices for Mounjaro without insurance range from approximately $550 to $1,100 per month depending on pharmacy and dose. Lilly's savings card program has historically reduced out-of-pocket costs for commercially insured patients, but eligibility requirements and benefit caps change frequently.

The practical implication for patients: a prescription written as "Mounjaro" for weight loss in a patient without diabetes will almost certainly be denied by insurance. If the patient qualifies for Zepbound (BMI ≥30, or ≥27 with comorbidity), that is the on-label pathway for coverage. The prescribing physician should document the appropriate diagnosis and use the correct brand name to maximize approval likelihood.

Compounded tirzepatide has entered the market through compounding pharmacies operating under FDA enforcement discretion during the shortage period. The FDA's position on compounded versions continues to evolve, and patients should understand that compounded products have not undergone the same manufacturing quality controls as FDA-approved tirzepatide [10].

Cardiovascular and Long-Term Safety Data

The SURPASS-CVOT (also called SUMMIT for heart failure and separate cardiovascular outcomes work) program is building the long-term safety case.

The SURMOUNT-MMO trial (estimated N=15,000) is designed to assess whether tirzepatide reduces major adverse cardiovascular events (MACE) in adults with obesity but without diabetes. Results are not expected before 2027.

Interim data are encouraging. In SURMOUNT-1, tirzepatide reduced systolic blood pressure by 6 to 8 mmHg, triglycerides by 19% to 25%, and C-reactive protein by 30% to 40% versus placebo [3]. These are directionally consistent with cardiovascular benefit, but surrogate markers are not outcomes.

For semaglutide, the SELECT trial [11] (N=17,604) demonstrated a 20% reduction in MACE among adults with overweight/obesity and established cardiovascular disease. No equivalent completed trial exists for tirzepatide as of this writing. Prescribers and patients should understand that cardiovascular outcomes data for tirzepatide in the non-diabetic obesity population remain pending.

The boxed warning for thyroid C-cell tumors is based on rodent data. Medullary thyroid carcinoma has been observed in rats treated with GLP-1 receptor agonists, though the clinical relevance to humans is uncertain. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome [12].

Who Should and Should Not Use Off-Label Mounjaro

Appropriate candidates for tirzepatide-based weight management (whether as Mounjaro off-label or Zepbound on-label) typically meet these criteria: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. They should have attempted behavioral modification (diet and exercise) without sufficient results.

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, MEN2, or known hypersensitivity to tirzepatide or any excipient. It should not be used during pregnancy. Animal studies showed fetal harm at clinically relevant exposures, and the prescribing information [12] recommends discontinuation at least two months before a planned pregnancy due to the drug's long half-life (approximately 5 days).

Caution is warranted in patients with a history of pancreatitis, severe gastrointestinal disease (gastroparesis in particular), or active gallbladder disease. Patients with type 1 diabetes should not use tirzepatide. Those with an eGFR <30 mL/min/1.73m² have limited representation in trials, and dose adjustments have not been formally studied in advanced kidney disease.

For patients already taking insulin or sulfonylureas for type 2 diabetes, adding tirzepatide requires dose reduction of the hypoglycemic agent to reduce the risk of severe hypoglycemia. The SURPASS trial program [13] provides specific guidance on insulin dose reductions when initiating tirzepatide.

The Weight Regain Problem

SURMOUNT-4 made the central challenge of pharmacological weight management impossible to ignore. After switching from tirzepatide to placebo, participants regained an average of 14.0 percentage points of body weight over 52 weeks [5]. Appetite scores returned toward baseline. Metabolic improvements in blood pressure and lipids partially reversed.

This pattern is not unique to tirzepatide. The STEP 1 extension trial showed similar regain with semaglutide discontinuation. The biological explanation is straightforward: obesity involves persistent changes in appetite-regulating hormones (ghrelin, leptin, GLP-1, PYY) that resist weight loss maintenance. Withdrawing the pharmacological counter-pressure allows these signals to reassert themselves.

The clinical implication is that tirzepatide for weight management is, for most patients, a long-term or indefinite commitment. Patients beginning this medication should plan for ongoing use and discuss with their prescriber what a realistic maintenance strategy looks like, including the possibility of dose reduction (SURMOUNT-4 suggested some patients maintained losses at lower doses) and the financial sustainability of indefinite treatment.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity [14] recommends that anti-obesity medications be continued as long as the patient is benefiting and tolerating the drug, with regular reassessment of risks and benefits at least annually.

Patients prescribed tirzepatide at any dose should have baseline thyroid function, lipase, and renal function assessed before starting therapy, with repeat labs at 3 and 12 months.